Avalo Therapeutics, Inc. filed a Form 10-Q with the SEC on November 5, 2026, reporting unaudited financial results for the quarterly period ended September 30, 2026, including a net loss of $74,933 thousand for the nine months ended September 30, 2026.
Real REMAX Group Inc. filed its quarterly report on Form 10-Q with the SEC for the period ended September 30, 2026, disclosing a significantly expanded balance sheet following what the filing describes as the combination of the legacy REMAX and Real businesses.
Evolent Health, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 5, 2026, covering the fiscal quarter ended September 30, 2026.
Shutterstock, Inc. filed a Form 8-K with the SEC on November 5, 2026, disclosing the appointment of Scott Grossman as Interim Chief Financial Officer effective November 2, 2026, alongside the departure of outgoing CFO Rik Powell, and announcing third-quarter 2026 financial results.
Shutterstock, Inc. filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the fiscal quarter ended September 30, 2026, disclosing balance sheet data including cash, receivables, and share count.
Shake Shack Inc. filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the thirteen and thirty-nine weeks ended September 30, 2026, and reporting total assets of $1,985,295 thousand as of that date.
Korro Bio, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 5, 2026, disclosing operational updates including its ongoing ANCHOR clinical trial and the pending termination of its Novo Nordisk collaboration.
Fate Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the three and nine months ended September 30, 2026, disclosing operational and financial information for its iPSC-derived cell therapy pipeline.
Commerce.com, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 5, 2026, reporting a net loss of $3.214 million for the third quarter while posting net income of $1.617 million for …
Entrada Therapeutics, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 5, 2026, covering the fiscal quarter ended September 30, 2026.